Efficacy of aripiprazole combined with olanzapine for hospitalized male patients with schizophrenia and its effect on metabolic syndrome

Autor: Liu Shunhua, Yuan Xiaofeng, Ye Xueting, Zhang Yuliang, Zhao Li, Zhou Kunyuan
Jazyk: čínština
Rok vydání: 2024
Předmět:
Zdroj: Sichuan jingshen weisheng, Vol 37, Iss 3, Pp 226-231 (2024)
Druh dokumentu: article
ISSN: 1007-3256
DOI: 10.11886/scjsws20230916001
Popis: BackgroundSchizophrenia and the use of antipsychotic medications are identified to be the likely contributors to the development of metabolic syndrome (MS) and cardiovascular disease, and jeopardize the prognosis of schizophrenia. Therefore, effectively preventing or reducing the risk of developing MS in patients with schizophrenia is critical.ObjectiveTo explore the efficacy of aripiprazole combined with olanzapine for male schizophrenia patients and its effect on MS, so as to provide a certain reference for the selection of antipsychotic drugs for schizophrenia patients.MethodsMale patients (n=80) who were hospitalized in The Third People's Hospital of Meizhou from February to June 2023 and fulfilling the International Classification of Diseases, tenth edition (ICD-10) diagnostic criteria for the schizophrenia were enrolled, and grouped using random number table method, each with 40 cases. Study group was treated with aripiprazole combined with olanzapine, while control group was given aripiprazole monotherapy. The treatment lasted for 6 continuous weeks in both groups. At the baseline, Positive and Negative Symptom Scale (PANSS) score, MS-related indices [fasting plasma glucose (FPG), hemoglobin A1c (HbA1c), body mass index (BMI), waist-to-hip ratio (WHR), lipid profile], S100 calcium-binding protein B (S100B) and high sensitivity C-reactive protein (hs-CRP) were recorded. Then the PANSS scores at the end of the 2nd, 4th and 6th week of treatment, the Clinical Global Impression (CGI) scores at the end of the 2nd and 6th week of treatment, as well as the MS-related indices, S100B, hs-CRP, Treatment Emergent Symptom Scale (TESS) score and Rating Scale for Extrapyramidal Side Effects (RSESE) score at the end of the 6th week of treatment were recorded in all participants.ResultsAnalysis on PANSS score revealed a significant group effect, time effect and group×time interaction effect (F=18.092, 634.780, 2.917, P
Databáze: Directory of Open Access Journals